VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
TLPHTalphera, Inc.
$1.09$46M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

TLPH logoTalphera, Inc.(TLPH)Earnings, Financials & Key Ratios

TLPH•NASDAQ
Price updated Jun 19, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryComplex generics and injectables
AboutTalphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.Show more
  • Revenue$28K
  • EBITDA-$14M+5.2%
  • Net Income-$14M-9.9%
  • EPS (Diluted)-0.34+32.0%
  • Gross Margin100%
  • EBITDA Margin-51296.43%
  • Operating Margin-48157.14%
  • Net Margin-51035.71%
  • ROE-114.16%+3.0%

TLPH Key Insights

Talphera, Inc. (TLPH) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Strong 5Y profit CAGR of 18.8%

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Sales declining 65.1% over 5 years
  • ✗Shares diluted 64.1% in last year
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when TLPH posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

TLPH Price & Volume

Talphera, Inc. (TLPH) stock price & volume — 10-year historical chart

Loading chart...

TLPH Growth Metrics

Talphera, Inc. (TLPH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-47.97%
5 Years-65.11%
3 Years-
TTM-96.3%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-22.42%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM20.41%

Return on Capital

10 Years-55.67%
5 Years-61.45%
3 Years-76.67%
Last Year-64.98%

TLPH Recent Earnings

Talphera, Inc. (TLPH) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 1/12 qtrs (50%)
Q2 2026Latest
May 13, 2026
Metric
Actual
Est
EPS
$0.04+42.9%
$0.07
Rev
—
—
Q2 2026
Mar 23, 2026
Metric
Actual
Est
EPS
$0.06+20.0%
$0.07
Rev
—
$580,000
Q4 2025
Nov 12, 2025
Metric
Actual
Est
EPS
$0.11-46.7%
$0.07
Rev
$1,000
—
Q3 2025
Aug 14, 2025
Metric
Actual
Est
EPS
$0.10+16.7%
$0.12
Rev
—
—
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 13, 2026
$0.04vs $0.07+42.9%
—
Q2 2026Mar 23, 2026
$0.06vs $0.07+20.0%
—vs $580,000
Q4 2025Nov 12, 2025
$0.11vs $0.07-46.7%
$1,000
Q3 2025Aug 14, 2025
$0.10vs $0.12+16.7%
—
Based on last 12 quarters of dataView full earnings history →

TLPH Peer Comparison

Talphera, Inc. (TLPH) competitors in Complex generics and injectables — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
PRGO logoPRGOPerrigo Company plcDirect Competitor1.42B10.25-1.00-2.75%-43.5%-50.65%1.35
HALO logoHALOHalozyme Therapeutics, Inc.Product Competitor8.13B68.5526.7837.55%23.13%126.27%43.89
NKTR logoNKTRNektar TherapeuticsProduct Competitor1.19B60.98-6.27-43.89%-284.18%-87%1.66
PCRX logoPCRXPacira BioSciences, Inc.Product Competitor878.35M22.33139.563.63%1.27%1.31%0.66
INVA logoINVAInnoviva, Inc.Product Competitor1.66B22.496.8218.52%118.91%47.59%0.23
MCK logoMCKMcKesson CorporationSupply Chain90.23B750.6319.5612.36%1.18%
CAH logoCAHCardinal Health, Inc.Supply Chain52.19B221.7734.38-1.87%0.62%
XTLB logoXTLBXTL Biopharmaceuticals Ltd.Often Compared279.46K2.54-0.26-227.72%-25.53%0.03

Compare TLPH vs Peers

Talphera, Inc. (TLPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PRGO

Most directly comparable listed peer for TLPH.

Scale Benchmark

vs MCK

Larger-name benchmark to compare TLPH against a more recognizable public peer.

Peer Set

Compare Top 5

vs PRGO, HALO, NKTR, PCRX

TLPH Income Statement

Talphera, Inc. (TLPH) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
8M2.15M2.29M5.42M378K0651K028K1K
Revenue Growth %
-53.94%-73.1%6.42%136.61%-93.02%-100%--100%--96.3%
Cost of Goods Sold
10.66M3.98M6.81M6.03M3.01M1.65M5.55M6.72M00
COGS % of Revenue
133.32%184.84%297.34%111.37%795.24%-851.92%---
Gross Profit
-2.66M▲ 0%
-1.82M▲ 31.5%
-4.52M▼ 147.5%
-616K▲ 86.4%
-2.63M▼ 326.6%
-1.65M▲ 37.3%
-4.89M▼ 197.2%
-6.72M▼ 37.2%
28K▲ 100.4%
1K▲ 0%
Gross Margin %
-33.32%-84.84%-197.34%-11.37%-695.24%--751.92%-100%100%
Gross Profit Growth %
-152.84%31.49%-147.51%86.36%-326.62%37.33%-197.21%-37.24%100.42%-
Operating Expenses
36.02M33.9M49.69M40.35M15.49M18.7M11.99M8.53M13.51M14.52M
OpEx % of Revenue
450.51%1576.1%2170.73%744.96%4097.35%-1842.4%-48257.14%-
Selling, General & Admin
16.61M20.77M45.03M36.33M017.01M007.48M8M
SG&A % of Revenue
207.74%965.36%1967.1%670.79%----26710.71%-
Research & Development
19.41M13.14M4.66M4.02M2.44M1.69M5.55M6.72M6.03M6.51M
R&D % of Revenue
242.76%610.74%203.63%74.17%644.18%-851.92%-21546.43%-
Other Operating Expenses
000013.05M06.45M1.82M00
Operating Income
-38.68M▲ 0%
-35.73M▲ 7.6%
-54.2M▼ 51.7%
-40.96M▲ 24.4%
-18.12M▲ 55.8%
-20.35M▼ 12.3%
-16.89M▲ 17.0%
-15.25M▲ 9.7%
-13.48M▲ 11.6%
-14.52M▲ 0%
Operating Margin %
-483.83%-1660.95%-2368.06%-756.33%-4792.59%--2594.32%--48157.14%-1451600%
Operating Income Growth %
-21.04%7.64%-51.72%24.43%55.77%-12.34%17.02%9.69%11.59%-
EBITDA
-36.94M-35.15M-52.54M-39.11M-16.14M-18.7M-16.79M-15.16M-14.36M-15.64M
EBITDA Margin %
-462.01%-1634.22%-2295.19%-722.12%-4270.63%--2579.57%--51296.43%-1564500%
EBITDA Growth %
-23.52%4.84%-49.46%25.56%58.72%-15.87%10.22%9.75%5.23%-42.97%
D&A (Non-Cash Add-back)
1.74M575K1.67M1.85M1.97M1.65M96K96K00
EBIT
-38.17M-34.59M-50.7M-37.07M-18.12M60.25M-16.89M-15.25M-14.36M-15.64M
Net Interest Income
-13.53M-11.42M968K588K871K386K6.6M-394K436K367K
Interest Income
510K1.14M3.5M3.89M3.16M1.5M6.74M0436K367K
Interest Expense
14.04M12.56M2.54M3.31M2.29M1.12M134K394K00
Other Income/Expense
-13.53M-11.42M968K588K969K79.49M6.6M2.25M-879K263K
Pretax Income
-52.21M▲ 0%
-47.15M▲ 9.7%
-53.24M▼ 12.9%
-40.38M▲ 24.2%
-17.15M▲ 57.5%
59.14M▲ 444.9%
-10.29M▼ 117.4%
-13M▼ 26.4%
-14.36M▼ 10.5%
-14.25M▲ 0%
Pretax Margin %
-653.02%-2191.86%-2325.78%-745.48%-4536.24%--1580.18%--51296.43%-1425300%
Income Tax
-701K2K3K4K5K13K0000
Effective Tax Rate %
1.34%-0%-0.01%-0.01%-0.03%0.02%0%0%0%0%
Net Income
-51.51M▲ 0%
-47.15M▲ 8.5%
-53.24M▼ 12.9%
-40.38M▲ 24.2%
-35.1M▲ 13.1%
42.52M▲ 221.1%
-18.4M▼ 143.3%
-13M▲ 29.3%
-14.29M▼ 9.9%
-14.25M▲ 0%
Net Margin %
-644.25%-2191.96%-2325.91%-745.55%-9285.45%--2825.96%--51035.71%-1425300%
Net Income Growth %
-19.35%8.46%-12.92%24.16%13.08%221.13%-143.27%29.31%-9.89%-22.42%
Net Income (Continuing)
-51.51M-47.15M-53.24M-40.38M-17.15M59.13M-10.29M-13M-14.36M-14.25M
Discontinued Operations
0000-17.95M-11.37M-8.11M073K0
Minority Interest
0000000000
EPS (Diluted)
-21.97▲ 0%
-16.14▲ 26.5%
-13.45▲ 16.7%
-9.47▲ 29.6%
-5.86▲ 38.1%
5.72▲ 197.6%
-1.29▼ 122.6%
-0.50▲ 61.2%
-0.34▲ 32.0%
-0.34▲ 0%
EPS Growth %
-15.33%26.54%16.67%29.59%38.12%197.61%-122.55%61.24%32%20.41%
EPS (Basic)
-21.97-16.14-13.45-9.47-5.865.73-1.29-0.50-0.34-
Diluted Shares Outstanding
2.34M2.92M3.96M4.26M5.99M7.41M14.26M25.85M42.41M42.41M
Basic Shares Outstanding
2.34M2.92M3.96M4.26M5.99M7.41M14.26M25.85M42.41M42.41M
Dividend Payout Ratio
----------

TLPH Balance Sheet

Talphera, Inc. (TLPH) balance sheet — assets, liabilities & shareholders' equity

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
63.41M107.99M71.69M46.83M50.49M24.57M11.56M9.42M20.9M21.34M
Cash & Short-Term Investments
60.47M105.72M66.14M42.89M46.63M15.77M9.38M8.86M20.38M21.11M
Cash Only
52.9M87.97M14.68M27.27M7.66M15.28M5.72M8.86M5.89M3.82M
Short-Term Investments
7.57M17.74M51.45M15.61M38.97M495K3.66M014.49M17.29M
Accounts Receivable
1.53M401K432K635K160K309K0000
Days Sales Outstanding
69.9968.0568.8942.79154.5-----
Inventory
956K854K3.29M1.63M1.11M1.18M0000
Days Inventory Outstanding
32.7478.4176.7198.39134.9261.06----
Other Current Assets
000002.31M-20K0519K228K
Total Non-Current Assets
12.14M12.54M19.67M19.46M27.4M22.92M8.84M8.82M8.82M8.82M
Property, Plant & Equipment
11.05M11.48M18.48M18.81M20.23M13.86M0000
Fixed Asset Turnover
0.72x0.19x0.12x0.29x0.02x-----
Goodwill
0000000000
Intangible Assets
000008.82M8.82M000
Long-Term Investments
881K529K00000000
Other Non-Current Assets
207K527K1.19M656K7.17M246K20K8.82M8.82M8.82M
Total Assets
75.55M▲ 0%
120.53M▲ 59.5%
91.36M▼ 24.2%
66.3M▼ 27.4%
77.89M▲ 17.5%
47.49M▼ 39.0%
20.39M▼ 57.1%
18.24M▼ 10.6%
29.72M▲ 63.0%
30.16M▲ 0%
Asset Turnover
0.11x0.02x0.03x0.08x0.00x-0.03x-0.00x0.00x
Asset Growth %
-24.44%59.54%-24.21%-27.43%17.49%-39.04%-57.05%-10.59%62.97%176.8%
Total Current Liabilities
13.66M15.93M13.61M17.64M18.51M13.77M4.51M2.65M3.81M4.03M
Accounts Payable
1.42M2.07M1.72M2.74M2.12M1.26M1.34M670K544K927K
Days Payables Outstanding
48.76190.0392.24165.62257.54278.3587.9336.4--
Short-Term Debt
8.33M9M4.98M8.73M8.8M5.36M0000
Deferred Revenue (Current)
362K315K0086K115K0000
Other Current Liabilities
2.19M3.61M411K155K2.97M2.8M1.17M723K3.27M3.1M
Current Ratio
4.64x6.78x5.27x2.66x2.73x1.78x2.56x3.56x5.49x5.30x
Quick Ratio
4.57x6.73x5.02x2.56x2.67x1.70x2.56x3.56x5.49x5.30x
Cash Conversion Cycle
53.96-43.58153.35-24.4331.86-----
Total Non-Current Liabilities
98.4M100.35M119.16M104.41M95.28M11.9M1.78M7.59M8.88M7.65M
Long-Term Debt
94.35M96.67M112.2M13.14M5.01M006.53M6.5M0
Capital Lease Obligations
003.64M2.61M3.75M2.96M0000
Deferred Tax Liabilities
0000000000
Other Non-Current Liabilities
585K537K3.32M88.66M85.37M7.91M1.78M1.06M2.38M7.65M
Total Liabilities
112.06M116.28M132.77M122.05M113.79M25.67M6.29M10.24M12.68M11.68M
Total Debt
102.68M105.67M121.79M25.6M18.62M10.02M06.53M6.5M0
Net Debt
49.78M17.7M107.11M-1.68M10.96M-5.25M-5.72M-2.34M605K-3.82M
Debt / Equity
-24.85x---0.46x-0.82x0.38x0.00x
Debt / EBITDA
----------0.00x
Net Debt / EBITDA
---------0.24x
Interest Coverage
-2.72x-2.75x-20.00x-11.22x-7.91x53.99x-126.04x-38.71x--
Total Equity
-36.51M▲ 0%
4.25M▲ 111.6%
-41.42M▼ 1073.9%
-55.75M▼ 34.6%
-35.89M▲ 35.6%
21.81M▲ 160.8%
14.11M▼ 35.3%
8M▼ 43.3%
17.04M▲ 112.9%
18.48M▲ 0%
Equity Growth %
-584.07%111.65%-1073.85%-34.6%35.62%160.78%-35.34%-43.28%112.91%393.9%
Book Value per Share
-15.571.46-10.46-13.08-5.992.950.990.310.400.44
Total Shareholders' Equity
-36.51M4.25M-41.42M-55.75M-35.89M21.81M14.11M8M17.04M18.48M
Common Stock
51K78K79K98K7K8K17K17K49K50K
Retained Earnings
-297.87M-345.02M-398.11M-438.49M-473.58M-425.83M-444.23M-457.23M-471.52M-474.08M
Treasury Stock
0000000000
Accumulated OCI
0000000000
Minority Interest
0000000000

TLPH Cash Flow Statement

Talphera, Inc. (TLPH) cash flow — operating, investing & free cash flow history

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
-29.77M-29.07M-51.18M-38.51M-30M-28.33M-17.49M-12.68M-11.36M-11.29M
Operating CF Margin %
-372.3%-1351.7%-2235.91%-710.95%-7937.04%--2686.94%--40585.71%-
Operating CF Growth %
-1.26%2.32%-76.03%24.77%22.08%5.57%38.26%27.49%10.4%44.5%
Net Income
-51.51M-47.15M-53.24M-40.38M-35.1M47.76M-18.4M-13M-14.29M-14.25M
Depreciation & Amortization
1.74M575K1.67M1.85M1.97M1.65M311K-121K-142K-125K
Stock-Based Compensation
4.29M5.17M5.06M4.42M4.61M2.89M1.73M989K699K503K
Deferred Taxes
00-11.84M712K810K02.2M000
Other Non-Cash Items
14.96M14.74M11.08M-2.83M-2.5M-79.23M-1.79M-323K1.29M431K
Working Capital Changes
3.7M1.87M-3.91M-2.29M203K-1.39M-1.54M-224K1.08M2.22M
Change in Receivables
3.6M1.48M-31K-203K475K-149K-189K000
Change in Inventory
920K102K-3.39M957K-295K-107K61K000
Change in Payables
309K458K-19K1.02M111K551K-575K-671K-208K347K
Cash from Investing
-9.97M-10.88M-36.56M34.14M-26.12M36.45M-528K3.78M-14.35M-17.06M
Capital Expenditures
-2.4M-819K-3.47M-1.85M-1.83M-364K-100K000
CapEx % of Revenue
30.08%38.08%151.59%34.25%483.33%-15.36%--0%
Acquisitions
0033.09M-35.99M-821K00000
Investments
----------
Other Investing
-7.57M-10.06M-33.09M35.99M0-1.69M2.72M000
Cash from Financing
12.33M75.03M14.45M16.96M41.51M-507K3.47M12.04M22.74M26.79M
Debt Issued (Net)
-3.51M-7.72M12.67M-4.67M-8.83M-8.43M-5.42M6.13M00
Equity Issued (Net)
15.69M81.53M1.23M21.34M50.28M7.91M8.86M5.91M22.74M26.79M
Dividends Paid
0000000000
Share Repurchases
0000000005K
Other Financing
147K1.22M553K286K69K16K26K000
Net Change in Cash
-27.41M▲ 0%
35.07M▲ 228.0%
-73.29M▼ 309.0%
12.59M▲ 117.2%
-14.61M▼ 216.1%
7.61M▲ 152.1%
-14.55M▼ 291.2%
3.14M▲ 121.6%
-2.97M▼ 194.5%
-1.56M▲ 0%
Free Cash Flow
-32.17M▲ 0%
-29.89M▲ 7.1%
-54.65M▼ 82.8%
-40.36M▲ 26.1%
-31.83M▲ 21.1%
-28.7M▲ 9.8%
-17.59M▲ 38.7%
-12.68M▲ 27.9%
-11.36M▲ 10.4%
-11.29M▲ 0%
FCF Margin %
-402.38%-1389.77%-2387.51%-745.2%-8420.37%--2702.3%--40585.71%-1129400%
FCF Growth %
2.85%7.07%-82.81%26.15%21.14%9.85%38.69%27.9%10.4%14.89%
FCF per Share
-13.72-10.24-13.80-9.47-5.31-3.87-1.23-0.49-0.27-0.27
FCF Conversion (FCF/Net Income)
0.58x0.62x0.96x0.95x0.85x-0.67x0.95x0.98x0.80x0.79x
Interest Paid
01.67M000837K0000
Taxes Paid
02K00000000

TLPH Key Ratios

Talphera, Inc. (TLPH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)
--1108.61%---194.9%-102.44%-117.65%-114.16%-92.98%
Return on Invested Capital (ROIC)
-261.81%-152.16%-92.78%-743.43%--92.16%-101.55%-162.84%-86.79%-80.13%
Gross Margin
-33.32%-84.84%-197.34%-11.37%-695.24%--751.92%-100%100%
Net Margin
-644.25%-2191.96%-2325.91%-745.55%-9285.45%--2825.96%--51035.71%-1425300%
Debt / Equity
-24.85x---0.46x-0.82x0.38x0.00x
Interest Coverage
-2.72x-2.75x-20.00x-11.22x-7.91x53.99x-126.04x-38.71x--
FCF Conversion
0.58x0.62x0.96x0.95x0.85x-0.67x0.95x0.98x0.80x0.79x
Revenue Growth
-53.94%-73.1%6.42%136.61%-93.02%-100%--100%--96.3%
Related:TLPH Dividend History·TLPH Revenue History·TLPH Price History·TLPH P/E History·TLPH Financial Ratios·TLPH Institutional Holders

TLPH SEC Filings & Documents

Talphera, Inc. (TLPH) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 13, 2026·SEC

Material company update

Mar 23, 2026·SEC

Material company update

Mar 16, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 23, 2026·SEC

FY 2025

Mar 31, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

May 13, 2026·SEC

FY 2025

Nov 12, 2025·SEC

FY 2025

Aug 14, 2025·SEC

TLPH Frequently Asked Questions

Talphera, Inc. (TLPH) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Talphera, Inc. (TLPH) reported $0.0M in revenue for fiscal year 2025.

Talphera, Inc. (TLPH) grew revenue by 0.0% over the past year. Growth has been modest.

Talphera, Inc. (TLPH) reported a net loss of $14.3M for fiscal year 2025.

Dividend & Returns

Talphera, Inc. (TLPH) has a return on equity (ROE) of -114.2%. Negative ROE indicates the company is unprofitable.

Talphera, Inc. (TLPH) had negative free cash flow of $11.3M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in TLPH back in 2008?

Total return calculator · dividends reinvested · 18+ years of data

See returns →

How much would $100/month in TLPH be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →